-
Mashup Score: 15
Bishal Gyawali: Looking back, 2024 was an excellent year / Abhenil Mittal, Abhinav Komanduri, Aditya Arkalgud, Alessandro Hammond, Arman Reza Chowdhury,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Government Funding for the Development of Enzalutamide - 1 month(s) ago
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Maybe you can do something about this @elonmusk @VivekGRamaswamy @DOGE @costplusdrugs https://t.co/73AbhJR1in https://t.co/IGv2T2ZEQz
-
-
Mashup Score: 2Government Funding for the Development of Enzalutamide - 1 month(s) ago
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Maybe you can do something about this @elonmusk @VivekGRamaswamy @DOGE @costplusdrugs https://t.co/73AbhJR1in https://t.co/IGv2T2ZEQz
-
-
Mashup Score: 2Government Funding for the Development of Enzalutamide - 1 month(s) ago
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Maybe you can do something about this @elonmusk @VivekGRamaswamy @DOGE @costplusdrugs https://t.co/73AbhJR1in https://t.co/IGv2T2ZEQz
-
-
Mashup Score: 2Government Funding for the Development of Enzalutamide - 1 month(s) ago
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Maybe you can do something about this @elonmusk @VivekGRamaswamy @DOGE @costplusdrugs https://t.co/73AbhJR1in https://t.co/IGv2T2ZEQz
-
-
Mashup Score: 2Government Funding for the Development of Enzalutamide - 1 month(s) ago
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Maybe you can do something about this @elonmusk @VivekGRamaswamy @DOGE @costplusdrugs https://t.co/73AbhJR1in https://t.co/IGv2T2ZEQz
-
-
Mashup Score: 7Who is a good teacher? - 1 month(s) ago
A good teacher is one whose goal is to make himself unnecessary. If you always need the teacher, that’s a bad teacher. If you always need the driving instructor to be in the car, that’s a bad drivi…
Source: bishalgyawali.comCategories: General Medicine News, Hem/OncsTweet-
My new blog post. Who is a good teacher/mentor ? https://t.co/rK2u7vRGd8
-
-
Mashup Score: 1अमेरिकन सोसाइटी अफ क्लिनिकल अंकोलोजीबाट फेलोसिप पाउने पहिलो नेपाली चिकित्सक बने डा. विशाल ज्ञवाली - 2 month(s) ago
काठमाडौँ, २१ मंसिर । नेपालका युवा अंकालोजिष्ट डा विशाल ज्ञवालीले संसारकै प्रसिद्ध मानिने अमेरिकन सोसाइटी अफ क्लिनिकल अंकोलोजीमा फेलोसिप प्राप्त गरेका छन् । हाल क्यानडाको क्वीन्स युनिभर्सिटीमा सहप्राध्यापकको रुपमा कार्यरत डा. ज्ञवाली यो फेलोसिप पाउने पहिलो नेपाली बनेका छन् ।
Source: www.nepalihealth.comCategories: General Medicine News, Hem/OncsTweet-
Thank you @nepalihealth. https://t.co/7eDilHIs8b https://t.co/mbxuDpb31l
-
-
Mashup Score: 1अमेरिकन सोसाइटी अफ क्लिनिकल अंकोलोजीबाट फेलोसिप पाउने पहिलो नेपाली चिकित्सक बने डा. विशाल ज्ञवाली - 2 month(s) ago
काठमाडौँ, २१ मंसिर । नेपालका युवा अंकालोजिष्ट डा विशाल ज्ञवालीले संसारकै प्रसिद्ध मानिने अमेरिकन सोसाइटी अफ क्लिनिकल अंकोलोजीमा फेलोसिप प्राप्त गरेका छन् । हाल क्यानडाको क्वीन्स युनिभर्सिटीमा सहप्राध्यापकको रुपमा कार्यरत डा. ज्ञवाली यो फेलोसिप पाउने पहिलो नेपाली बनेका छन् ।
Source: www.nepalihealth.comCategories: General Medicine News, Hem/OncsTweet-
Thank you @nepalihealth. https://t.co/7eDilHIs8b https://t.co/mbxuDpb31l
-
-
Mashup Score: 1
Several factors informed HTA outcomes for new cancer medicines. A high ESMO-MCBS score, defined as indicating substantial clinical benefit, increased the likelihood of a positive HTA outcome and shortened the interval between marketing authorisation and HTA outcome, and this association was not affected by other variables. Additional factors informing HTA outcomes include evidence uncertainties and unmet medical need. Country-relevant differences exist in the time-to-HTA outcome and the propensity of some countries to achieve positive (restricted or unrestricted) outcomes compared with others.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
RT @kjmeetswrld: https://t.co/DALj9Gx0JE Great study by @KanavosPG @aris_angelis and Erica Visintin on the use of @myESMO in #HTA recommen…
-
Highlights of 2024 from Team Gyawali, thanks to @oncodaily. https://t.co/Obtdv2pgcF